Cost-utility analysis of inotuzumab ozogamicin for refractory or relapsed B-cell acute lymphoblastic leukemia
MA Guoqiang, ZHENG Miaomiao, HONG Wanglong, ZHU Wentao, SHEN Aizong
Chinese Journal of Hospital Pharmacy ›› 2023, Vol. 43 ›› Issue (20) : 2275-2279.
Cost-utility analysis of inotuzumab ozogamicin for refractory or relapsed B-cell acute lymphoblastic leukemia
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 | 〉 |